Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a strong-buy rating to a buy rating in a research report released on Tuesday morning.

Several other research analysts also recently commented on the company. The Goldman Sachs Group assumed coverage on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, July 12th. They issued a buy rating on the stock. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a neutral rating in a research report on Monday, August 14th. Citigroup began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 1st. They issued a neutral rating for the company. Truist Financial boosted their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $26.00 to $28.00 and gave the stock a hold rating in a research report on Thursday, July 13th. Finally, Morgan Stanley boosted their price objective on shares of Fresenius Medical Care AG & Co. KGaA to €40.50 ($43.55) in a research report on Wednesday, August 16th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of Hold and an average target price of $29.89.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.4 %

NYSE FMS opened at $21.31 on Tuesday. The company has a market capitalization of $12.51 billion, a price-to-earnings ratio of 20.30 and a beta of 1.06. The company has a current ratio of 1.26, a quick ratio of 0.91 and a debt-to-equity ratio of 0.47. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $12.78 and a 1-year high of $27.72. The stock’s 50 day moving average is $24.90 and its two-hundred day moving average is $23.00.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Wednesday, August 2nd. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.19 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 5.15% and a net margin of 3.01%. Equities analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.2 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently made changes to their positions in the business. Comerica Bank bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $140,000. Wells Fargo & Company MN increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 16.5% in the 2nd quarter. Wells Fargo & Company MN now owns 30,034 shares of the company’s stock valued at $719,000 after buying an additional 4,245 shares in the last quarter. Atlas Capital Advisors LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $71,000. Goldman Sachs Group Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 58.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 736,847 shares of the company’s stock valued at $17,633,000 after buying an additional 272,886 shares in the last quarter. Finally, Morningstar Investment Services LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $224,000. Institutional investors own 5.81% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.